{"transactions":[{"id":2110437,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-11-18T21:05:18.000Z","date":"2022-11-16","kind":"sale","acquired":false,"shares":16074,"price":7.4983,"value":120527.6742,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.39 to $7.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":333726,"source":{"system":"sec-edgar","filing":"0000899243-22-036362","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322036362/doc4.xml","form_type":"4"}},{"id":2116261,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-11-15T21:53:12.000Z","date":"2022-11-11","kind":"sale","acquired":false,"shares":36592,"price":8.1959,"value":299904.3728,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 4, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":349800,"source":{"system":"sec-edgar","filing":"0000899243-22-035893","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322035893/doc4.xml","form_type":"4"}},{"id":2120106,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-11-10T22:29:58.000Z","date":"2022-11-10","kind":"sale","acquired":false,"shares":13109,"price":8.0022,"value":104900.8398,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 4, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":386392,"source":{"system":"sec-edgar","filing":"0000899243-22-035551","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322035551/doc4.xml","form_type":"4"}},{"id":2120105,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-11-10T22:29:58.000Z","date":"2022-11-08","kind":"sale","acquired":false,"shares":299,"price":8,"value":2392.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 4, 2022."}],"balance_after":399501,"source":{"system":"sec-edgar","filing":"0000899243-22-035551","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322035551/doc4.xml","form_type":"4"}},{"id":2131652,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-10-26T20:15:24.000Z","date":"2022-10-20","kind":"sale","acquired":false,"shares":1070,"price":9.3607,"value":10015.949,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":399800,"source":{"system":"sec-edgar","filing":"0000899243-22-034262","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322034262/doc4a.xml","form_type":"4/A","original_submission_date":"2022-10-24"}},{"id":2133015,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-10-24T22:26:03.000Z","date":"2022-10-19","kind":"sale","acquired":false,"shares":1070,"price":9.3607,"value":10015.949,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":399800,"source":{"system":"sec-edgar","filing":"0000899243-22-034059","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322034059/doc4.xml","form_type":"4"}},{"id":2165769,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-09-06T20:17:41.000Z","date":"2022-09-02","kind":"sale","acquired":false,"shares":493,"price":7.8888,"value":3889.1784,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.85 to $7.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":400870,"source":{"system":"sec-edgar","filing":"0000899243-22-030423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322030423/doc4.xml","form_type":"4"}},{"id":2181868,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-08-17T21:58:13.000Z","date":"2022-08-16","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares reported in this transaction represent RSUs issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on August 16, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":401363,"source":{"system":"sec-edgar","filing":"0000899243-22-029045","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322029045/doc4.xml","form_type":"4"}},{"id":2181867,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-08-17T21:58:13.000Z","date":"2022-08-16","kind":"sale","acquired":false,"shares":15590,"price":8.3049,"value":129473.391,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.12 to $8.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":386363,"source":{"system":"sec-edgar","filing":"0000899243-22-029045","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322029045/doc4.xml","form_type":"4"}},{"id":2203976,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-07-21T23:11:17.000Z","date":"2022-07-20","kind":"sale","acquired":false,"shares":1058,"price":5.2145,"value":5516.941,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.15 to $5.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":401953,"source":{"system":"sec-edgar","filing":"0000899243-22-026516","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322026516/doc4.xml","form_type":"4"}},{"id":2212092,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-06T11:30:18.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":26000,"derivative":{"exercise_price":4.13,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0000899243-22-025233","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322025233/doc4.xml","form_type":"4"}},{"id":2212091,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-07-06T11:30:18.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares reported in this transaction represent RSUs issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":403011,"source":{"system":"sec-edgar","filing":"0000899243-22-025233","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322025233/doc4.xml","form_type":"4"}},{"id":2212090,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-07-06T11:30:18.000Z","date":"2022-06-03","kind":"sale","acquired":false,"shares":515,"price":3.6321,"value":1870.5315,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\"), and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.60 to $3.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":389011,"source":{"system":"sec-edgar","filing":"0000899243-22-025233","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322025233/doc4.xml","form_type":"4"}},{"id":2265824,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-05-18T12:57:20.000Z","date":"2022-05-17","kind":"sale","acquired":false,"shares":15262,"price":4.4009,"value":67166.5358,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.31 to $4.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":389526,"source":{"system":"sec-edgar","filing":"0000899243-22-018526","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322018526/doc4.xml","form_type":"4"}},{"id":2291872,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-04-22T12:28:39.000Z","date":"2022-04-20","kind":"sale","acquired":false,"shares":852,"price":6.6843,"value":5695.0236,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.665 to $6.6976. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":404788,"source":{"system":"sec-edgar","filing":"0000899243-22-015393","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322015393/doc4.xml","form_type":"4"}},{"id":2308493,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-04T20:22:30.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":56744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":56744,"derivative":{"exercise_price":9.15,"expiration_date":"2032-01-18","underlying":"Common Stock","underlying_shares":56744},"source":{"system":"sec-edgar","filing":"0000899243-22-013331","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322013331/doc4.xml","form_type":"4"}},{"id":2308492,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-04-04T20:22:30.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":23256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":405640,"source":{"system":"sec-edgar","filing":"0000899243-22-013331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322013331/doc4.xml","form_type":"4"}},{"id":2354930,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-03-03T21:15:47.000Z","date":"2022-03-02","kind":"sale","acquired":false,"shares":516,"price":9.0143,"value":4651.3788,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.01 to $9.015. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":382384,"source":{"system":"sec-edgar","filing":"0000899243-22-009059","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322009059/doc4.xml","form_type":"4"}},{"id":2385624,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-02-18T21:30:44.000Z","date":"2022-02-16","kind":"sale","acquired":false,"shares":15322,"price":8.323,"value":127525.006,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.15 to $8.74. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":382900,"source":{"system":"sec-edgar","filing":"0000899243-22-007029","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322007029/doc4.xml","form_type":"4"}},{"id":2427843,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-24T21:15:25.000Z","date":"2022-01-20","kind":"sale","acquired":false,"shares":4656,"price":8.7526,"value":40752.1056,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.49 to $9.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":398222,"source":{"system":"sec-edgar","filing":"0000899243-22-003004","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322003004/doc4.xml","form_type":"4"}},{"id":2486095,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T21:14:46.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":514,"price":17.0627,"value":8770.2278,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.79 to $17.41. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":402878,"source":{"system":"sec-edgar","filing":"0000899243-21-046758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321046758/doc4.xml","form_type":"4"}},{"id":2504992,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-18T21:30:45.000Z","date":"2021-11-16","kind":"sale","acquired":false,"shares":15203,"price":21.1315,"value":321262.1945,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.52 to $21.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":403392,"source":{"system":"sec-edgar","filing":"0000899243-21-045272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321045272/doc4.xml","form_type":"4"}},{"id":2554489,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:58:27.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":3413,"price":25.0732,"value":85574.8316,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":418595,"source":{"system":"sec-edgar","filing":"0000899243-21-038676","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321038676/doc4.xml","form_type":"4"}},{"id":2554488,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:58:27.000Z","date":"2021-09-30","kind":"sale","acquired":false,"shares":12171,"price":25.1659,"value":306294.1689,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.46. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":422008,"source":{"system":"sec-edgar","filing":"0000899243-21-038676","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321038676/doc4.xml","form_type":"4"}},{"id":2554487,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:58:27.000Z","date":"2021-09-29","kind":"sale","acquired":false,"shares":1000,"price":25.0367,"value":25036.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":434179,"source":{"system":"sec-edgar","filing":"0000899243-21-038676","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321038676/doc4.xml","form_type":"4"}},{"id":2564115,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-20T22:33:15.000Z","date":"2021-09-17","kind":"sale","acquired":false,"shares":5916,"price":25.0781,"value":148362.0396,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":435179,"source":{"system":"sec-edgar","filing":"0000899243-21-036636","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321036636/doc4.xml","form_type":"4"}},{"id":2564114,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-20T22:33:15.000Z","date":"2021-09-02","kind":"sale","acquired":false,"shares":513,"price":19.86,"value":10188.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."}],"balance_after":441095,"source":{"system":"sec-edgar","filing":"0000899243-21-036636","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321036636/doc4.xml","form_type":"4"}},{"id":2564113,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-20T22:33:15.000Z","date":"2021-08-17","kind":"sale","acquired":false,"shares":15205,"price":17.82,"value":270953.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."}],"balance_after":441608,"source":{"system":"sec-edgar","filing":"0000899243-21-036636","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321036636/doc4.xml","form_type":"4"}},{"id":2564112,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-20T22:33:15.000Z","date":"2021-06-03","kind":"sale","acquired":false,"shares":508,"price":22.87,"value":11617.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."}],"balance_after":456813,"source":{"system":"sec-edgar","filing":"0000899243-21-036636","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321036636/doc4.xml","form_type":"4"}},{"id":2564111,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-20T22:33:15.000Z","date":"2021-05-18","kind":"sale","acquired":false,"shares":15201,"price":22.8,"value":346582.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."}],"balance_after":457321,"source":{"system":"sec-edgar","filing":"0000899243-21-036636","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321036636/doc4.xml","form_type":"4"}},{"id":2564110,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-20T22:33:15.000Z","date":"2021-03-02","kind":"sale","acquired":false,"shares":512,"price":37.93,"value":19420.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"As previously reported, the reporting person sold 17,100 shares of Common Stock between February 17, 2021 and March 2, 2021."}],"balance_after":472522,"source":{"system":"sec-edgar","filing":"0000899243-21-036636","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321036636/doc4.xml","form_type":"4"}},{"id":2564109,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-20T22:33:15.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":15196,"price":39.65,"value":602521.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."}],"balance_after":490134,"source":{"system":"sec-edgar","filing":"0000899243-21-036636","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321036636/doc4.xml","form_type":"4"}},{"id":2814236,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:36:15.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":1600,"price":39.2081,"value":62732.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.075 to $39.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":488230,"source":{"system":"sec-edgar","filing":"0001209191-21-017534","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121017534/doc4.xml","form_type":"4"}},{"id":2814235,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:36:15.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":4332,"price":38.6197,"value":167300.5404,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.06 to $38.945. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":489830,"source":{"system":"sec-edgar","filing":"0001209191-21-017534","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121017534/doc4.xml","form_type":"4"}},{"id":2839629,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-24T00:44:13.000Z","date":"2021-02-23","kind":"sale","acquired":false,"shares":700,"price":40.3243,"value":28227.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.03 to $40.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":494162,"source":{"system":"sec-edgar","filing":"0001209191-21-013485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013485/doc4.xml","form_type":"4"}},{"id":2839628,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-24T00:44:13.000Z","date":"2021-02-23","kind":"sale","acquired":false,"shares":1418,"price":39.1794,"value":55556.3892,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.75 to $39.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":494862,"source":{"system":"sec-edgar","filing":"0001209191-21-013485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013485/doc4.xml","form_type":"4"}},{"id":2839627,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-24T00:44:13.000Z","date":"2021-02-22","kind":"sale","acquired":false,"shares":2200,"price":42.8186,"value":94200.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.42 to $43.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":496280,"source":{"system":"sec-edgar","filing":"0001209191-21-013485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013485/doc4.xml","form_type":"4"}},{"id":2839626,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-24T00:44:13.000Z","date":"2021-02-22","kind":"sale","acquired":false,"shares":600,"price":41.5283,"value":24916.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.27 to $41.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":498480,"source":{"system":"sec-edgar","filing":"0001209191-21-013485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013485/doc4.xml","form_type":"4"}},{"id":2839625,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-24T00:44:13.000Z","date":"2021-02-19","kind":"sale","acquired":false,"shares":4165,"price":41.7094,"value":173719.651,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.41 to $42.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":499080,"source":{"system":"sec-edgar","filing":"0001209191-21-013485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013485/doc4.xml","form_type":"4"}},{"id":2846421,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-19T13:41:41.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":750,"price":41.5009,"value":31125.675,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.22 to $41.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":503245,"source":{"system":"sec-edgar","filing":"0000899243-21-007332","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007332/doc4.xml","form_type":"4"}},{"id":2846420,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-19T13:41:41.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":800,"price":40.4368,"value":32349.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.22 to $40.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":503995,"source":{"system":"sec-edgar","filing":"0000899243-21-007332","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007332/doc4.xml","form_type":"4"}},{"id":2846419,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-19T13:41:41.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":535,"price":39.8349,"value":21311.6715,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.21 to $40.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":504795,"source":{"system":"sec-edgar","filing":"0000899243-21-007332","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007332/doc4.xml","form_type":"4"}},{"id":2850560,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-19T02:20:22.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":100,"price":41.56,"value":4156.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."}],"balance_after":505330,"source":{"system":"sec-edgar","filing":"0000899243-21-007272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007272/doc4.xml","form_type":"4"}},{"id":2850559,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-19T02:20:22.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":1300,"price":41.2168,"value":53581.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.56 to $41.46. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":505430,"source":{"system":"sec-edgar","filing":"0000899243-21-007272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007272/doc4.xml","form_type":"4"}},{"id":2850558,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-19T02:20:22.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":400,"price":39.7187,"value":15887.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.22 to $40.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":506730,"source":{"system":"sec-edgar","filing":"0000899243-21-007272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007272/doc4.xml","form_type":"4"}},{"id":2850557,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-19T02:20:22.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":500,"price":38.424,"value":19212.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.20 to $38.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":507130,"source":{"system":"sec-edgar","filing":"0000899243-21-007272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007272/doc4.xml","form_type":"4"}},{"id":2850556,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-19T02:20:22.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":400,"price":42.5225,"value":17009.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.21 to $43.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":507630,"source":{"system":"sec-edgar","filing":"0000899243-21-007272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007272/doc4.xml","form_type":"4"}},{"id":2850555,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-19T02:20:22.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":2700,"price":41.7632,"value":112760.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.21 to $42.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":508030,"source":{"system":"sec-edgar","filing":"0000899243-21-007272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007272/doc4.xml","form_type":"4"}},{"id":2879271,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-04T21:35:26.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":48910,"price":41.19,"value":2014602.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."}],"balance_after":510730,"source":{"system":"sec-edgar","filing":"0000899243-21-004952","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321004952/doc4.xml","form_type":"4"}},{"id":2900865,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-22T00:24:20.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":65000,"derivative":{"exercise_price":42.15,"expiration_date":"2031-01-19","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0000899243-21-002758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321002758/doc4.xml","form_type":"4"}},{"id":2900864,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-01-22T00:24:20.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":559640,"source":{"system":"sec-edgar","filing":"0000899243-21-002758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321002758/doc4.xml","form_type":"4"}},{"id":3067696,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-08-06T01:55:06.000Z","date":"2020-08-03","kind":"exercise","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6710},"source":{"system":"sec-edgar","filing":"0000899243-20-021585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021585/doc4.xml","form_type":"4"}},{"id":3067695,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-08-06T01:55:06.000Z","date":"2020-08-03","kind":"purchase","acquired":true,"shares":3000,"price":17,"value":51000.0,"ownership":{"direct":true},"balance_after":524640,"source":{"system":"sec-edgar","filing":"0000899243-20-021585","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021585/doc4.xml","form_type":"4"}},{"id":3067694,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-08-06T01:55:06.000Z","date":"2020-08-03","kind":"exercise","acquired":true,"shares":6710,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."}],"balance_after":521640,"source":{"system":"sec-edgar","filing":"0000899243-20-021585","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021585/doc4.xml","form_type":"4"}},{"id":3072595,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-31T22:39:50.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":237200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on July 29, 2021, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":237200,"derivative":{"exercise_price":17,"expiration_date":"2030-07-29","underlying":"Common Stock","underlying_shares":237200},"source":{"system":"sec-edgar","filing":"0000899243-20-020921","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320020921/doc4.xml","form_type":"4"}},{"id":3878367,"issuer":{"id":122050,"kind":"organization","name":"Tricida, Inc.","symbol":"TCDA"},"owners":[{"id":122271,"kind":"person","name":"VAN BEEK JEROEN B","position":1,"cik":"0001743662","reported_name":"VAN BEEK JEROEN B","relationship":{"officer":true,"officer_title":"Chief Comm Officer and Sr VP"}}],"security":"Common Stock","published_at":"2018-07-02T20:55:47.000Z","date":"2018-07-02","kind":"purchase","acquired":true,"shares":5264,"price":19,"value":100016.0,"ownership":{"direct":true},"balance_after":5264,"source":{"system":"sec-edgar","filing":"0001140361-18-031047","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1595585/000114036118031047/form4.xml","form_type":"4"}}]}